Fahadul Alam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fahadul Alam has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Mohammad Chand Jamali
College of Medical and Health Sciences, Liwa University, Al Ain, Abu Dhabi, United Arab Emirates
2 shared publications - Nikolaos Syrmos
School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
2 shared publications - Srikumar Chakravarthi
Faculty of Medicine, Nursing and Health Sciences, SEGi University, Selangor, Malaysia
2 shared publications - Hrishik Iqbal
Quest Bangladesh Biomedical Research Center, Bangladesh
1 shared publication - Md.SHajalal Reza
Lecturer, Department of Pharmacy,Hamdard University Bangladesh,Gazaria, Munshigonj
1 shared publication Mohammad Nazmul Islam
1 shared publication
Latest Publications
- 1 July 2026
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 19 (7) , 3393-3400
Antimicrobial Resistance as a Global Public Health Crisis at the Nexus of Bacteriology and Sustainable Development
The problem of antimicrobial resistance (AMR) has become one of the most acute global healthcare-related issues, as multidrug-resistant organisms (MDROs) have become the cause of the extensive morbidity and death rate both in healthcare and general community. AMR spread places a geographical burden on the population because of differences in health infrastructure, antimicrobial abuse and environmental exposure. Surveillance data provided by tools such as the WHO GLASS show the level of resistance is especially high in Southeast Asia, the Eastern Mediterranean, and Sub-Saharan Africa. The trend in Latin America is a growth in community as well as hospital-acquired infections caused by ESBL-producing Enterobacteriaceae, whereas in Europe there are trends of rising resistance levels in Klebsiella pneumoniae and E. coli. On the other hand, a few of the highly developed states claim MRSA stabilization and downfall. International travel and trade have further contributed to the spread of resistance genes lik20260e NDM and mcr around the globe increasing the crisis. The most vulnerable groups are children, aged people, and those who have a compromised immune system as it is more likely to happen in low- and middle-income countries (LMICs). The economic impact of AMR on health systems is burdened by the prolonged hospital stays and the cost of treatment, and this is estimated to cost an annual USD 88 billion globally. To curb the AMR as a transnational and cross departmental challenge, limited development pipeline of new antibiotics and the increased resistance to last-line treatments require immediate investments by the globe in surveillance, access, innovation, and stewardship.
- 1 July 2026
- Published by A and V Publications in Research Journal of Pharmacy and Technology
- Vol. 19 (7) , 3393-3400
Antimicrobial Resistance as a Global Public Health Crisis at the Nexus of Bacteriology and Sustainable Development
The problem of antimicrobial resistance (AMR) has become one of the most acute global healthcare-related issues, as multidrug-resistant organisms (MDROs) have become the cause of the extensive morbidity and death rate both in healthcare and general community. AMR spread places a geographical burden on the population because of differences in health infrastructure, antimicrobial abuse and environmental exposure. Surveillance data provided by tools such as the WHO GLASS show the level of resistance is especially high in Southeast Asia, the Eastern Mediterranean, and Sub-Saharan Africa. The trend in Latin America is a growth in community as well as hospital-acquired infections caused by ESBL-producing Enterobacteriaceae, whereas in Europe there are trends of rising resistance levels in Klebsiella pneumoniae and E. coli. On the other hand, a few of the highly developed states claim MRSA stabilization and downfall. International travel and trade have further contributed to the spread of resistance genes lik20260e NDM and mcr around the globe increasing the crisis. The most vulnerable groups are children, aged people, and those who have a compromised immune system as it is more likely to happen in low- and middle-income countries (LMICs). The economic impact of AMR on health systems is burdened by the prolonged hospital stays and the cost of treatment, and this is estimated to cost an annual USD 88 billion globally. To curb the AMR as a transnational and cross departmental challenge, limited development pipeline of new antibiotics and the increased resistance to last-line treatments require immediate investments by the globe in surveillance, access, innovation, and stewardship.
- Open Access
- 6 October 2025
- Published by Universa Medicina in Universa Medicina
- Vol. 44 (3)
Bortezomib in multiple myeloma management
Multiple myeloma (MM) is a hematologic malignancy characterized by the uncontrolled proliferation of plasma cells, leading to complications such as bone lesions, renal dysfunction, and immune suppression. Over the past three decades, its incidence has risen significantly, attributed to factors such as aging populations and improved diagnostic methods. Treatment strategies have evolved considerably, transitioning from alkylating agents and high-dose chemotherapy to targeted therapies, including proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs). Bortezomib, a first-in-class PI, has revolutionized MM management by inhibiting proteasome activity, thereby inducing apoptosis in malignant plasma cells. This review evaluates the efficacy, safety, and clinical applications of bortezomib, both as monotherapy and in combination with dexamethasone, IMiDs, and conventional chemotherapies. Key clinical trials, such as VISTA and SUMMIT, demonstrate its superiority over traditional regimens, improving response rates and survival outcomes. However, its use is associated with adverse effects, including peripheral neuropathy, hematologic toxicities, and gastrointestinal disturbances, necessitating dose modifications and supportive care. Emerging combinations with monoclonal antibodies and novel agents further enhance therapeutic potential, though optimal sequencing remains under investigation. Systematic literature search was performed using PubMed and Cochrane to identify relevant studies on the applications of bortezomib. The search was inclusive of all publications up to May 2025, without restriction by publication year, to ensure a thorough review of research on bortezomib. Studies focusing on multiple myeloma (MM) and the efficacy of bortezomib were prioritized. A broad set of keywords was employed reflecting the diverse applications of bortezomib in MM treatment. The search strategy was designed to capture a wide range of relevant studies. By synthesizing evidence from 77 studies, this review highlights bortezomib’s pivotal role in MM treatment while addressing challenges in toxicity management. Future research should focus on refining combination strategies and minimizing side effects to maximize long-term patient outcomes.
- 6 October 2025
- Published by Universa Medicina in Universa Medicina
- Vol. 44 (3)
Open AccessBortezomib in multiple myeloma management
Multiple myeloma (MM) is a hematologic malignancy characterized by the uncontrolled proliferation of plasma cells, leading to complications such as bone lesions, renal dysfunction, and immune suppression. Over the past three decades, its incidence has risen significantly, attributed to factors such as aging populations and improved diagnostic methods. Treatment strategies have evolved considerably, transitioning from alkylating agents and high-dose chemotherapy to targeted therapies, including proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs). Bortezomib, a first-in-class PI, has revolutionized MM management by inhibiting proteasome activity, thereby inducing apoptosis in malignant plasma cells. This review evaluates the efficacy, safety, and clinical applications of bortezomib, both as monotherapy and in combination with dexamethasone, IMiDs, and conventional chemotherapies. Key clinical trials, such as VISTA and SUMMIT, demonstrate its superiority over traditional regimens, improving response rates and survival outcomes. However, its use is associated with adverse effects, including peripheral neuropathy, hematologic toxicities, and gastrointestinal disturbances, necessitating dose modifications and supportive care. Emerging combinations with monoclonal antibodies and novel agents further enhance therapeutic potential, though optimal sequencing remains under investigation. Systematic literature search was performed using PubMed and Cochrane to identify relevant studies on the applications of bortezomib. The search was inclusive of all publications up to May 2025, without restriction by publication year, to ensure a thorough review of research on bortezomib. Studies focusing on multiple myeloma (MM) and the efficacy of bortezomib were prioritized. A broad set of keywords was employed reflecting the diverse applications of bortezomib in MM treatment. The search strategy was designed to capture a wide range of relevant studies. By synthesizing evidence from 77 studies, this review highlights bortezomib’s pivotal role in MM treatment while addressing challenges in toxicity management. Future research should focus on refining combination strategies and minimizing side effects to maximize long-term patient outcomes.